* Sales -1% vs cons, adj. EBITA -14%, but North America guided to grow in Q1e * 2026 guidance: "Bett...
Redeye expects a negative share price reaction to InfraCom's Q4 2025 results.
* We expect nearly 40% organic growth... * ...and gross margin expansion in '26e * Reiterate fair va...
Redeye comments on Formpipe’s Q4 report, which shows weak ACV but solid profitability.
Från ett spretigt bygge till en skalbar SaaS-maskin – Carasents historik och tidigare svaga sentimen...
Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25...
Surgical Science delivered a decent but slightly soft Q4, facing near-term headwinds from the Intuit...
* An EBIT increase to SEK 6m (3m) in Q4'25 * We raise EBIT by 2-3% for '26e-'27e * Well positioned f...
* Orders +4%, sales +6%, adj. EBITA +15% vs. ABGSCe * Guides for 2.
Net sales and adj. EBITA were slightly below market consensus (LSEG) in Q4.
* Sales +34% vs EBIT adj. EUR 3.9m vs. ABGSCe 0.7m * Orders in line vs.
Redeye updates its estimates and valuation after OEM’s Q4 2025 report.
Redeye presents its preview for Paxman’s Q4 2025 report, due on February 27.
Recent years have been quite volatile for Incap. Quarterly revenue growth fluctuated between +40% an...
* Q4: +27% sales growth, 1.5% EBITDA margin * '26e-'27e EBITDA up 2-3% * Continues to show improveme...
* Accretive SBBs set to continue in H1'26 * Room for M&A to drive earnings growth * 2026e P/CEPS 11x...
* Strong Q4, with EBIT 82% ahead of our forecast * We lift '26e EBIT by 17% on positive sales revisi...
Redeye was surprised to see organic sales growth of 10% in the fourth quarter.
Flowscape avslutar 2025 med historiskt positiv EBIT på årsbasis (2,2 mkr).
Redeye views the Q4 report as a sizable top-line beat, exceeding forecasts by 110% despite the quart...
